
0:00
7:00
It's a quiet week for acromegaly-specific research — no top-tier trials, just a handful of diagnostic and mechanistic papers — while rare disease industry news brought two new FDA approvals (Priovant's Lisraya for dermatomyositis and Takeda/Protagonist's Mimrylo for polycythemia vera) that show regulators keep clearing novel mechanisms for small patient populations.
More episodes from "Acromegaly Update"



Don't miss an episode of “Acromegaly Update” and subscribe to it in the GetPodcast app.








